The company’s continued growth in revenue can be attributed to product penetration and continued expansion of a direct sales force. Bacterin expects to see continued revenue growth acceleration with its expanded sales force and two recently launched biologics scaffolds: Osteosponge SC and hMatrix.
Read the company news release about Bacterin’s first quarter financial results.
Related Articles on Device Company Financial Results:
SANUWAVE Posts Q1 $252K Revenue, 76% Increase
TranS1 Reports $5.1M in Q1 Revenues, 24% Decrease
DJO Global Reports $249.7M in Q1 Net Sales
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
